Results 21 to 30 of about 8,073 (209)
PDE5 inhibitors for LUTS [PDF]
Prostate Cancer and Prostatic Diseases, 2009 To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990-2009) data regarding epidemiologic and pathophysiologic mechanisms are involved in LUTS-ED, focusing on
S, Mouli, K T, McVary
openaire +2 more sources
The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis. [PDF]
Exp Biol Med (Maywood), 2017 The results in our study appear to establish the osteoporosis model and provide evidence of the positive effects of three separate PDE5 inhibitors (vardenafil, udenafil, and tadalafil).
Alp HH +5 more
europepmc +2 more sources
PDE5 inhibitors beyond erectile dysfunction [PDF]
International Journal of Impotence Research, 2007 The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with these compounds.
P, Sandner +4 more
openaire +2 more sources
Translational Oncology, 2020 Widespread cGMP-specific phosphodiesterase 5 (PDE5) inhibitor use in male reproductive health and particularly in prostate cancer patients following surgery has generated interest in how these drugs affect the ability of residual tumor cells to ...
William Hankey +8 more
doaj +1 more source
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
Pharmaceuticals, 2023 Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes.
Ahmed K. ElHady +3 more
doaj +1 more source
Current use of phosphodiesterase inhibitors in urology
Urology Research and Practice, 2019 The causes of male erectile dysfunction (ED) are quite variable and are now commonly divided into etiologies such as ischemia, smooth muscle damage, or altered blood flow.
Tariq Said Hakky, Lakshay Jain
doaj +1 more source
Effects of the recreational use of PDE5 inhibitors on the corpus cavernosum of young, healthy rats [PDF]
, 2014 PDE5 inhibitors are widely used for the treatment of erectile dysfunction. However, these drugs have recently become popular among men without erectile dysfunction as a means of enhancing sexual performance and improving sexual desire.
Alkan, Faruk +5 more
core +1 more source
Substituted Pyrazolopyridines as Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile Dysfunction [PDF]
, 2016 Substituted Pyrazolopyridines as Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile ...
John Krupinski (1745206) +13 more
core +1 more source
Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
Urological Science, 2016 Erectile dysfunction (ED) is a prevalent form of male sexual dysfunction. Phosphodiesterase type 5 (PDE5) inhibitor is the first-line treatment for ED. Numerous well-designed and -conducted clinical trials and postmarketing studies have established the ...
Bang-Ping Jiann
doaj +1 more source
PDE5 inhibitors and permanent visual loss [PDF]
International Journal of Impotence Research, 2005 Nonarteritic anterior ischemic optic neuropathy (NAION), a form of optic nerve stroke, has received attention as the result of a possible rare association with PDE5 inhibitors (PDE5i). The possible mechanism of the PDE5i interaction with NAION is unclear, and the sporadic case reports do not seem to shed light on this topic. There is little guidance on
openaire +2 more sources